The Society of Gynecologic Oncology and ASCCP endorse this document. USPSTF Cervical Cancer Screening Recommendations for Average-Risk. As with the updates, the new ACS/ASCCP/ASCP guidelines suggest a . Comparison of Cervical Cancer Screening Guidelines. Co-testing is preferable to using a Pap test alone for women ages 30– 1 ACS, ASCCP, & ASCP guidelines update In March

Author: Megul Maull
Country: Djibouti
Language: English (Spanish)
Genre: Spiritual
Published (Last): 20 September 2012
Pages: 43
PDF File Size: 7.55 Mb
ePub File Size: 20.6 Mb
ISBN: 449-3-44370-364-7
Downloads: 95057
Price: Free* [*Free Regsitration Required]
Uploader: Macage

Cytology every three years liquid or conventional.

This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.

Women who have received the HPV vaccination. For more information visit www. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference.

ACS/ASCCP/ASCP Guidelines for the Early Detection of Cervical Cancer

Discontinue if three negative Pap smear results or two negative HPV test results in past 10 years, if most recent test was within the past five years. Information from references 1 and Annual screening of women at any age is not recommended because it results in only a slightly greater reduction in cancer risk but twice the number of colposcopies compared with screening every three years.

Therefore, these women should not be referred directly for colposcopy. When CIN3 is found in women of any age, treatment is recommended.

On August 21,the U. The potential harm outweighs the small potential benefit of screening women in this age group. Agency for Healthcare Research and Quality; The short-term risk of CIN3 in these women is far less than when an HPV-positive test is associated with atypical squamous cells of undetermined significance ASCUS or with low-grade squamous intraepithelial lesions, and most transient infections clear within 12 months.


The major change from the USPSTF guidelines is that for average-risk women aged 30—65 years, the USPSTF now recommends high-risk human papillomavirus hrHPV testing alone every 5 years as an alternative to screening with cervical cytology alone every 3 years or screening with a combination of cytology and hrHPV testing every 5 years.

There is no role for testing for low-risk genotypes, and tests for low-risk HPV should not be performed. It is appropriate to counsel average-risk women aged 30— 65 years regarding all three strategies so that they can select their preferred option. Same as for unvaccinated women. More in Pubmed Citation Related Articles. New research shows lower risk of existing abnormalities than previously thought and provides guidance on use of HPV testing.

The guidelines state that women younger than 21 years should not be screened for cervical cancer, regardless of age of sexual initiation or other risk factors. Get immediate access, anytime, anywhere. Cervical Cancer Screening Update. If HPV- routine screening with cotesting in 5 years is indicated. The new USPSTF recommendations emphasize that the choice of screening strategy should consider the balance of benefit disease detection and potential harms more frequent follow-up testing, invasive diagnostic procedures, and unnecessary treatment in women with false-positive results and involve shared decision making between patients and their health care providers.

Because the KPNC follow up of patients covers less than 10 years, more time will be needed to see if these women can return to routine screening after multiple negative follow-up tests. It is not intended to substitute for guiselines independent professional judgment of the treating clinician.

A Decision Analysis for the U. These low-risk women are at high risk for HPV exposure and lesions, and should be observed.


Guidelines are intended for use only with HPV tests that have been analytically and clinically validated, as documented by Food and Drug Administration FDA licensing and approval or publication in peer-reviewed scientific literature Management based on results of HPV tests that have not been similarly validated may yuidelines result in outcomes intended by these guidelines and may increase the potential for patient harm.

The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence.

Consensus Guidelines FAQs – ASCCP

Want to use this article elsewhere? Most new HPV infections in women older than 65 years clear spontaneously. Like the USPSTF recommendations, these expert guidelines recognize that cytology alone, hrHPV testing alone, and co-testing are all effective screening strategies for average-risk women aged 30—65 years.

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Read the full article. Testing should be restricted to high-risk oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary.

See My Options close Already a member or subscriber? Women with similar risks should be managed similarly. Abnormal vaginal cytology is seldom of clinical importance.

Reprints are not available from the authors.